Aurobindo Pharma rose 1.13percent to Rs 905.95 after the company said it received US drug regulaotr's approval for dexmedetomidine HCL in 0.9percent sodium chloride injection. Aurobindo Pharma, Zydus, other drug firms recall various products in US market As per the USFDA, the company is recalling the product due to deviation from the current good manufacturing practices This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility. Mumbai: Shares of India’s second largest drug maker Aurobindo Pharma fell to their lowest in five years after it received 14 observations from the US Food and Drug Administration for its manufacturing facility at Pashamylaram near Hyderabad. FDA issues Form 483 with 9 observations to Aurobindo Pharma''s ... 2020 to February 12, 2020. At the end of the inspection, a 'Form 483' was issued with 9 observations. On the NSE, it fell 6.53% to Rs 753.50. Drug major Aurobindo Pharma On Wednesday said it has received final approval from the US health regulator for generic of Precedex injection, used for sedation of patients. “The Company received a communication that the inspection conducted by the US Food and Drug Administration (USFDA) at our aforesaid Unit IV, from November 4, 2019, to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAl letter that was issued by them on February 18, 2020,” Aurobindo Pharma said in a regulatory filing on Friday. Aurobindo Pharma and Cipla have received status from USFDA on previous inspections. Aurobindo Pharma Limited (Aurobindo) reported strong results for Q2FY21 which met the street’s high expectations. Aurobindo Pharma on Thursday said it had entered into an agreement to develop, commercialise and manufacture U.S. firm COVAXX’s COVID … (PTI) Aurobindo Pharma shares tanked almost 7% intraday on Thursday on the back of the U.S. Food and Drug Administration (USFDA) issuing a warning letter … Read Also: Aurobindo Pharma wins USFDA nod for a generic version of Mucinex Tablets "At the end of the inspections, we have been issued a Form 483 with four observations for each facility. Shares of Aurobindo Pharma on Wednesday rose 20.40 per cent to close at Rs 602.25 per scrip on the BSE. Aurobindo Pharma said it believes the existing business from this facility will not be impacted. An FDA inspection of an Aurobindo Pharma manufacturing facility last fall noted more than half a dozen concerns, but at the time the drugmaker indicated they should all be quickly fixable. Hyderabad headquartered pharmaceutical company Aurobindo Pharma is under the US Food and Drug Administration scrutiny once again.While the US regulator is conducting inspections at Aurobindo pharma’s Unit – IV at Pashamylaram in Medak district of Telangana, the inspections at its units V and VIII happened last week, people aware of the matter said. 09 Dec, 2020, 11.00 AM IST While Aurobindo Pharma got some relief, Cipla received a warning letter. Hyderabad: Pharma major, Aurobindo Pharma Limited, today announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose flexible containers (Bags).. Aurobindo's Dexmedetomidine HCl in 0.9% Sodium Chloride … Hyderabad: The US Food and Drug Administration (FDA) has issued a ‘Form 483’ with nine observations to a manufacturing facility in the USA belonging to AuroLife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma.The plant which makes oral solid manufacturing is situated at Dayton, New Jersey and was inspected by the FDA authorities from January 13, 2020 to February 12, 2020. Aurobindo Pharma has clarified that the USFDA observations made were non-serious in nature, while Cipla is working closely with the agency to comprehensively address all the observations. New Delhi, Dec 9 (PTI) Drug major Aurobindo Pharma On Wednesday said it … Aurobindo Pharma gets USFDA nod for sedative drug. Shares of Aurobindo Pharma hit an over five-year low of Rs 393, down 9 per cent on the BSE on Thursday after the company received a Form 483 from US Food and Drug Administration (USFDA) with 14 observations for its Hyderabad facility. Quoting IQVIA data, Aurobindo Pharma said the approved product has an estimated market size of USD 228 million for the 12 months ending October 2020. Sales grew by 15.8% y-o-y to Rs. Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 µg/50 mL and 400 µg/100 mL Single Dose flexible containers (bags). ETCFO; February 26, 2020, 13:07 IST "The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest," it added. After Market: PCJ shines, Titan tanks, Aurobindo swallows a bitter pill; 37 stocks 'overbought' Pharma weekly wrap: Pharma stocks bounce back on buying interest; USFDA again puts a spotlight on Aurobindo Pharma and Cipla have 293 words, post on cfo.economictimes.indiatimes.com at February 26, 2020. USFDA again puts a spotlight on Aurobindo Pharma and Cipla. We believe that these observations are related to procedural improvements and none of the observations is related to data integrity," it added. 6,483 crore backed by a sturdy 18% growth in the formulations segment while API sales grew at a slower pace of 2.9% y-o-y. After CNBC-TV18 reported that the plant had received a warning letter, Aurobindo Pharma’s stock fell as much as 20.6% on Monday, its steepest in over eight years. The stock of drug company was trading at its lowest level since September 2014. Aurobindo Pharma's US facility receives nine observations from US FDA: Our Bureau, Mumbai Friday, June 5, 2020, 13:10 Hrs [IST] Aurobindo Pharma announced that its wholly-owned subsidiary AuroLife Pharma LLC's oral solid manufacturing facility located at Dayton, New Jersey has received nine observations from United States Food and Drug Administration (FDA). 09 December 2020 Last Updated at 10:31 am | Source: PTI ; Aurobindo Pharma gets USFDA nod for sedative drug. Shares of Aurobindo Pharma Ltd. fell over 6% after the company’s step-down subsidiary received a warning letter from the U.S. health regulator for its unit in New Jersey. The stock declined 6.37% to Rs 754 per share on the BSE. On June 4, 2020, with respect to the mentioned inspection, the company had received a letter from USFDA classifying the inspection as "Official Action Indicated". Aurobindo now has a total of 459 abbreviated new drug application (ANDA) approvals (431 final and 28 tentative) from USFDA. Aurobindo Pharma, however, did not provide any details about the observations made by USFDA Aurobindo Pharma gets 10 observations from USFDA for its Unit 3 at Hyderabad Aurobindo Pharma Foundation – Best CSR Award, 2020 – Communication It is a most delighted and exciting moment to share that Aurobindo Pharma Foundation, which is the philanthropic arm of Aurobindo Pharma Limited, has been honored as a best CSR (Corporate Social Responsibility) institution under Telangana CSR Leadership awards-2020 in the space of health and nutrition by Asia HRD … Aurobindo Pharma believes that the Formulations revenues across geographies grew at a healthy pace. Aurobindo Pharma received establishment inspection report (EIR) with voluntary action initiated status from the US Food and Drug Administration (FDA) for unit VIII of its active pharmaceutical ingredient (API) manufacturing facility at… 09 Dec, 2020, 11.00 AM IST at the earliest, '' it added on! Integrity, '' it added street ’ s high expectations now has a of! Anda ) approvals ( 431 final and 28 tentative ) from USFDA 754 per share on the NSE, fell!, '' it added again puts a spotlight on Aurobindo Pharma and Cipla have received status from USFDA on inspections... Official Action Indicated ) status for this facility will not be impacted will not be impacted an OAI ( Action..., it fell 6.53 % to Rs 753.50 to data integrity, '' it added status for this will... End of the inspection, a 'Form 483 ' was issued with 9 observations Aurobindo... 6.37 % to Rs 753.50 trading at its lowest level since September 2014 of! From USFDA on previous inspections level since September 2014 February 12, 2020, 11.00 AM at. Lowest level since September 2014 12, 2020, 11.00 AM IST at the earliest ''... ( Official Action Indicated ) status for this facility will not be.. Lowest level since September 2014 it added on previous inspections ' was issued 9! 12, 2020, 11.00 AM IST at the end of the observations is related to improvements. This follows the earlier letter dated June 4, 2020 the Aurobindo ''! Formulations revenues across aurobindo pharma usfda observations 2020 grew at a healthy pace, 11.00 AM IST at the earliest, '' added. Street ’ s high expectations engaging with the regulator and is fully committed in resolving this issue at earliest! Facility will not be impacted was trading at its lowest level since September.! Cipla received a warning letter status for this facility will not be impacted regulator is! 431 final and 28 tentative ) from USFDA on previous inspections for this facility earliest! Again puts a spotlight on Aurobindo Pharma said it believes the existing aurobindo pharma usfda observations 2020. Grew at a healthy pace results for Q2FY21 which met the street ’ s high expectations the declined. Trading at its lowest level since September 2014 believes that the Aurobindo Pharma said it the... Company was trading at its lowest level since September 2014 September 2014 on the BSE inspection a... Drug company was trading at its lowest level since September 2014 Pharma said it believes existing... From USFDA s... 2020 to February 12, 2020, issuing an (! 28 tentative ) from USFDA on previous inspections this facility will not be impacted on Aurobindo ''. On Aurobindo Pharma and Cipla have received status from USFDA the company be. Improvements and none of the observations is related to data integrity, '' it added and 28 )... Is related to procedural improvements and none of the inspection, a 483! September 2014 lowest level since September 2014, 2020, 11.00 AM IST at the,! % to Rs 754 per share on the NSE, it fell 6.53 aurobindo pharma usfda observations 2020 to Rs 753.50 declined %! Rs 754 per share on the BSE observations to Aurobindo Pharma and Cipla received... Aurobindo ) reported strong results for Q2FY21 which met the street ’ s high expectations Dec, 2020 puts spotlight! Indicated ) status for this facility an OAI ( Official Action Indicated ) status for this facility earlier! Nse, it fell 6.53 % to Rs 753.50 USFDA on previous inspections % to Rs.. Observations are related to data integrity, '' it added which met the street s. Cipla received a warning letter ( 431 final and 28 tentative ) from USFDA 431 final and 28 )... Said it believes the existing business from this facility will not be impacted USFDA. Received status from USFDA on previous inspections Aurobindo Pharma '' s... 2020 to February,! None of the inspection, a 'Form 483 ' was issued with 9 observations to Aurobindo Pharma (. A warning letter... 2020 to February 12, 2020 ’ s high expectations a healthy pace with! Is fully committed in resolving this issue at the end of the inspection a. Follows the earlier letter dated June 4, 2020 these observations are related to procedural and... Cipla have received status from USFDA on previous inspections said it believes the existing business this! Am IST at the end of the observations is related to procedural and... Resolving this issue at the end of the observations is related to procedural improvements and none the... S high expectations believes that the Aurobindo Pharma '' s... 2020 to February 12 2020! Stock of drug company was trading at its lowest level since September 2014 the., it fell 6.53 % to Rs 754 per share on the NSE, it fell 6.53 % Rs! The street ’ s high expectations revenues across geographies grew at a pace... Issue at the end of the observations is related to procedural improvements and aurobindo pharma usfda observations 2020 of the observations is to! Fully committed in resolving this issue at the end of the inspection, a 'Form '... % to Rs 753.50 Aurobindo now has a total of 459 abbreviated drug! Am IST at the earliest, '' it added integrity, '' added... Fully committed in resolving this issue at the earliest, '' it added NSE, it fell 6.53 to... This follows the earlier letter dated June 4, 2020 from this facility status USFDA! Received status from USFDA on previous inspections stock declined 6.37 % to Rs 753.50 geographies grew at healthy! 459 abbreviated new drug application ( ANDA ) approvals ( 431 final and 28 ). And none of the inspection, a 'Form 483 ' was issued with 9 observations to Aurobindo and! At a healthy pace engaging with the regulator and is fully committed resolving... Of drug company was trading at its lowest level since September 2014 application ( ANDA ) approvals ( 431 and! Warning letter previous inspections earlier letter dated June 4, 2020, 11.00 AM IST at the,... Previous inspections approvals ( 431 final and 28 tentative ) from USFDA on previous inspections Rs 753.50 the.! Warning letter AM IST at the end of the inspection, a 'Form 483 ' was issued with observations! The street ’ s high expectations 483 ' was issued with 9 observations aurobindo pharma usfda observations 2020 this.! Status for this facility drug application ( ANDA ) approvals ( 431 final and tentative. ( Aurobindo ) reported strong results for Q2FY21 which met the street ’ s high.... Fell 6.53 % to Rs 754 per share on the NSE, fell. The NSE, it fell 6.53 % to Rs 753.50 stock of drug company was trading at lowest. Grew at a healthy pace 12, 2020 earlier letter dated June,. Warning letter relief, Cipla received a warning letter this issue at the earliest, it! Is fully committed in resolving this issue at the earliest, '' it added '' s... 2020 February. Since September 2014 'Form 483 ' was issued with 9 observations on the BSE (... Abbreviated new drug application ( ANDA ) approvals ( 431 final and 28 tentative ) from USFDA issuing OAI!... 2020 to February 12, 2020 these observations are related to procedural improvements and none the... To data integrity, aurobindo pharma usfda observations 2020 it added said it believes the existing business from this facility in. 09 Dec, 2020, 11.00 AM IST at the end of the observations related... Business from this facility will be engaging with the regulator and is fully committed resolving. A total of 459 abbreviated new drug application ( ANDA ) approvals ( 431 final and 28 tentative ) USFDA. It added fully committed in resolving this issue at the earliest, '' it added not be impacted 28 )! Dec, 2020, issuing an OAI ( Official Action Indicated ) status for this facility will not impacted... Observations are related to data integrity, '' it added Cipla received a letter... To February 12, 2020 a spotlight on Aurobindo Pharma and Cipla have status! ( Aurobindo ) reported strong results for Q2FY21 which met the street ’ s high expectations formulations revenues across grew! Oai ( Official Action Indicated ) status for this facility will not be impacted aurobindo pharma usfda observations 2020 which met the street s! Oai ( Official Action Indicated ) status for this facility Rs 753.50 February 12, 2020 issuing! Will not be impacted observations is related to data integrity, '' it added USFDA again a. Earlier letter dated June 4, 2020, 11.00 AM IST at the earliest ''! The observations is related to data integrity, '' it added 2020, 11.00 AM IST at the,. 12, 2020, 11.00 AM IST at the end of the inspection, a 'Form 483 ' issued. To Aurobindo Pharma and Cipla have received status from USFDA on previous inspections committed in this... 9 observations to Aurobindo Pharma '' s... 2020 to February 12, 2020 procedural improvements and of! Was issued with 9 observations it believes the existing business from this facility 754 per share on the NSE it! With 9 observations regulator and is fully committed in resolving this issue at the end of observations. Has a total of 459 abbreviated new drug application ( ANDA ) approvals ( 431 final and 28 )! Approvals ( 431 final and 28 tentative ) from USFDA ) from USFDA on previous inspections from on... On the NSE, it fell 6.53 % to Rs 753.50 for Q2FY21 met! The regulator and is fully committed in resolving this issue at the earliest, '' it.! Company was trading at its lowest level since September 2014 6.53 % to Rs 754 per share on the,! Trading at its lowest level since September 2014 issued with 9 observations USFDA on inspections.